REVIEW published: 18 November 2020 doi: 10.3389/fendo.2020.597573 Growth Hormone Receptor Regulation in Cancer and Chronic Diseases Edited by: † † Ralf Jockers, Ger J. Strous 1,2*, Ana Da Silva Almeida 1 , Joyce Putters 1 , Julia Schantl 1, Universite´ de Paris, France † † † † Magdalena Sedek 1 , Johan A. Slotman 1 , Tobias Nespital 1 , Gerco C. Hassink 1 Reviewed by: and Jan A. Mol 3* Vincent Goffin, ´ Universite Paris Descartes, France 1 Department of Cell Biology, Centre for Molecular Medicine, University Medical Centre Utrecht, Utrecht, Netherlands, Roman L. Bogorad, 2 BIMINI Biotech B.V., Leiden, Netherlands, 3 Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Puretech Health, Inc., United States Medicine, Utrecht University, Utrecht, Netherlands *Correspondence: Ger J. Strous
[email protected]; The GHR signaling pathway plays important roles in growth, metabolism, cell cycle
[email protected] control, immunity, homeostatic processes, and chemoresistance via both the JAK/STAT Jan A. Mol and the SRC pathways. Dysregulation of GHR signaling is associated with various
[email protected] diseases and chronic conditions such as acromegaly, cancer, aging, metabolic †Present addresses: Ana Da Silva Almeida, disease, fibroses, inflammation and autoimmunity. Numerous studies entailing the GHR Biogen, Cambridge, signaling pathway have been conducted for various cancers. Diverse factors mediate the MA, United States fi Joyce Putters, up- or down-regulation of GHR signaling through post-translational modi cations. Of the Department of Life, Environment, numerous modifications, ubiquitination and deubiquitination are prominent events. and Health, Dutch Ubiquitination by E3 ligase attaches ubiquitins to target proteins and induces Research Council (NWO) The Hague, Netherlands proteasomal degradation or starts the sequence of events that leads to endocytosis Magdalena Sedek, and lysosomal degradation.